The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124

Meng,Qingbing; Zhang,Wensheng; Xu,Xingli; Li,Jian; Mu,Hongxin; Liu,Xiaolan; Qin,Ling; Zhu,Xiaoqi; Zheng,Minqian

doi:10.3892/ijmm.2018.3458

The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124

Authors:
- Qingbing Meng
- Wensheng Zhang
- Xingli Xu
- Jian Li
- Hongxin Mu
- Xiaolan Liu
- Ling Qin
- Xiaoqi Zhu
- Minqian Zheng
View Affiliations

Affiliations: Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224005, P.R. China
Published online on: February 5, 2018 https://doi.org/10.3892/ijmm.2018.3458
Pages: 2968-2976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to verify tumor necrosis factor receptor‑associated factor 6 (TRAF6) as the target gene of microRNA-124 (miR-124). In addition, the expression of miR‑124 was investigated in osteosarcoma tissues and cells, and its effects on the biological characteristics of osteosarcoma cells were determined, in order to provide an experimental and theoretical basis for the application of TRAF6 in the treatment of osteosarcoma. A fluorescence reporter enzyme system was used to verify TRAF6 as a target gene of miR‑124, and western blotting was used to detect the effects of miR‑124 on the protein expression levels of TRAF6 in cells. The expression levels of miR‑124 were detected in osteosarcoma tissues and an osteosarcoma cell line (MG‑63) by quantitative polymerase chain reaction (qPCR). In addition, a total of 48 h post‑transfection of MG‑63 cells with a miR‑124 mimic, qPCR was used to detect the expression levels of miR‑124, and the effects of miR‑124 on the viability of MG‑63 human osteosarcoma cells was determined using the MTT method. The effects of miR‑124 on the cell cycle progression and apoptosis of MG‑63 cells were analyzed by flow cytometry, whereas the effects of miR‑124 on the migration of MG‑63 cells was detected using the Transwell invasion chamber analysis method. A TRAF6 recombinant expression plasmid (pcDNA3.1‑TRAF6) was also constructed, and MG‑63 cells were transfected with the recombinant plasmid and a miR‑124 mimic, in order to further validate the biological role of miR‑124 via the regulation of TRAF6. The results of the present study indicated that, compared with in the normal control group, the expression levels of miR‑124 were significantly increased in MG‑63 cells transfected with a miR‑124 mimic (P<0.01). In addition, the luciferase reporter gene system demonstrated that, compared with in the control group, relative luciferase activity was significantly reduced in the miR‑124 mimic group (P<0.01). The results of MTT analysis indicated that cell viability was also significantly reduced in response to the overexpression of miR‑124 in MG‑63 cells (P<0.01). Flow cytometric analysis demonstrated that the proportion of cells in S phase and G2/M phase was significantly decreased (P<0.01) in cells overexpressing miR‑124, and the number of apoptotic cells was significantly increased (P<0.01). Furthermore, the results of the Transwell invasion assay suggested that the number of invasive cells was significantly decreased following enhanced expression of miR‑124 (P<0.01). In MG‑63 cells overexpressing miR‑124 and TRAF6, the results of MTT, flow cytometric and Transwell assay analyses demonstrated that the overexpression of TRAF6 had the opposite biological effects compared to miR‑124 overexpression. In conclusion, the present study indicated that the expression levels of miR‑124 were downregulated in human osteosarcoma tissues and cells, and that miR‑124 is associated with negative regulation of TRAF6 expression; therefore, the role of TRAF6 in primary osteosarcoma may be regulated by miR‑124. Therapeutic strategies that enhance miR‑124 expression or inhibit TRAF6 expression may be beneficial for the treatment of patients with osteosarcoma.

View Figures

View References

1	Lugowska I, Mierzejewska E, Lenarcik M, Klepacka T, Koch I, Michalak E and Szamotulska K: The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults. Tumour Biol. 37:12071–12078. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS, Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapy. Pediatr Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jiang H, Liu W, Li G, Fan T and Mao B: Chinese medicinal herbs in the treatment of upper airway cough syndrome: A systematic review of randomized, controlled trials. Altern Ther Health Med. 22:38–51. 2016.PubMed/NCBI
4	Wang L, Yang L, Lu Y, Chen Y, Liu T, Peng Y, Zhou Y, Cao Y, Bi Z, Liu T, et al: Osthole induces cell cycle arrest and inhibits migration and invasion via PTEN/Akt pathways in osteosarcoma. Cell Physiol Biochem. 38:2173–2182. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ali Gumustas S, Isyar M, Topuk S, Yilmaz I, Oznam K, Onay T, Ofluoglu O and Mahirogullari M: Systematic evaluation of drug-loaded hydrogels for application in osteosarcoma treatment. Curr Pharm Biotechnol. 17:866–872. 2016. View Article : Google Scholar : PubMed/NCBI
6	Kebudi R, Ozger H, Kızılocak H, Bay SB and Bilgiç B: Osteosarcoma after hematopoietic stem cell transplantation in children and adolescents: Case Report and Review of the Literature. Pediatr Blood Cancer. 63:1664–1666. 2016. View Article : Google Scholar : PubMed/NCBI
7	Cheng L, Wang C and Jing J: Cell cycle kinases in osteosarcoma: Potential for therapeutic intervention. Curr Pharm Des. 22:4830–4834. 2016. View Article : Google Scholar : PubMed/NCBI
8	Maximov VV and Aqeilan RI: Genetic factors conferring metastasis in osteosarcoma. Future Oncol. 12:1623–1644. 2016. View Article : Google Scholar : PubMed/NCBI
9	Li X, Zhang Y, Wan S, Li H, Li D, Xia J, Yuan Z, Ren M, Yu S, Li S, et al: A comparative study between limb-salvage and amputation for treating osteosarcoma. J Bone Oncol. 5:15–21. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wan J and Zhang X, Liu T and Zhang X: Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett. 11:511–520. 2016. View Article : Google Scholar : PubMed/NCBI
11	Durham BH, Diamond EL and Abdel-Wahab O: Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol. 23:416–425. 2016. View Article : Google Scholar : PubMed/NCBI
12	Cagle PT, Raparia K and Portier BP: Emerging biomarkers in personalized therapy of lung cancer. Adv Exp Med Biol. 890:25–36. 2016. View Article : Google Scholar
13	Krishna A, Singh S, Kumar V and Pal US: Molecular concept in human oral cancer. Natl J Maxillofac Surg. 6:9–15. 2015. View Article : Google Scholar : PubMed/NCBI
14	De P, Carlson JH, Leyland-Jones B and Dey N: Role of 'oncogenic nexus' of CIP2A in breast oncogenesis: How does it work? Am J Cancer Res. 5:2872–2891. 2015.
15	Luo Z, Zhang X, Zeng W, Su J, Yang K, Lu L, Lim CB, Tang W, Wu L, Zhao S, et al: TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin. Oncotarget. 7:7179–7192. 2016.PubMed/NCBI
16	Han F, Zhang L, Qiu W and Yi X: TRAF6 promotes the invasion and metastasis and predicts a poor prognosis in gastric cancer. Pathol Res Pract. 212:31–37. 2016. View Article : Google Scholar
17	Lin FT, Lin VY, Lin VT and Lin WC: TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation. Cell Discov. 2:150482016. View Article : Google Scholar : PubMed/NCBI
18	Zhao T, Tang X, Umeshappa CS, Ma H, Gao H, Deng Y, Freywald A and Xiang J: Simulated microgravity promotes cell apoptosis through suppressing Uev1A/TICAM/TRAF/NF-κB-regulated anti-apoptosis and p53/PCNA- and ATM/ATR-Chk1/2-controlled DNA-damage response pathways. J Cell Biochem. 117:2138–2148. 2016. View Article : Google Scholar : PubMed/NCBI
19	Panda S, Nilsson JA and Gekara NO: Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes. Immunity. 43:647–659. 2015. View Article : Google Scholar : PubMed/NCBI
20	Tomomura M, Suzuki R, Shirataki Y, Sakagami H, Tamura N, Tomomura A and Rhinacanthin C: Rhinacanthin C inhibits osteoclast differentiation and bone resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 signaling. PLoS One. 10:e01301742015. View Article : Google Scholar
21	Kong X, Yang Y, Wu W, Wan H, Li X, Zhong M, Su X, Jia S and Lin N: Triterpenoid saponin W3 from Anemone flaccida suppresses osteoclast differentiation through inhibiting activation of MAPKs and NF-κB pathways. Int J Biol Sci. 11:1204–1214. 2015. View Article : Google Scholar :
22	Kong X, Wu W, Yang Y, Wan H, Li X, Zhong M, Zhao H, Su X, Jia S, Ju D, et al: Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation. J Transl Med. 13:912015. View Article : Google Scholar
23	He Z, Huang C, Lin G and Ye Y: siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells. Oncol Rep. 35:1933–1940. 2016. View Article : Google Scholar : PubMed/NCBI
24	Peng Z, Shuangzhu Y, Yongjie J, Xinjun Z and Ying L: Retraction note to: TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem. 415:2072016. View Article : Google Scholar
25	Han Q, Yao F, Zhong C and Zhao H: TRAF6 promoted the metastasis of esophageal squamous cell carcinoma. Tumour Biol. 35:715–721. 2014. View Article : Google Scholar
26	Sun H, Li XB, Meng Y, Fan L, Li M and Fang J: TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis. Cancer Res. 73:4950–4959. 2013. View Article : Google Scholar : PubMed/NCBI
27	Meng Q, Zheng M, Liu H, Song C, Zhang W, Yan J, Qin L and Liu X: TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem. 371:177–186. 2012. View Article : Google Scholar : PubMed/NCBI
28	Peng S, Gao D, Gao C, Wei P, Niu M and Shuai C: MicroRNAs regulate signaling pathways in osteogenic differentiation of mesenchymal stem cells (Review). Mol Med Rep. 14:623–629. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yeh CH, Moles R and Nicot C: Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 15:372016. View Article : Google Scholar : PubMed/NCBI
30	Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang Y, et al: miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget. 7:16205–16216. 2016.PubMed/NCBI
31	Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
32	Denduluri SK, Wang Z, Yan Z, Wang J, Wei Q, Mohammed MK, Haydon RC, Luu HH and He TC: Molecular pathogenesis and therapeutic strategies of human osteosarcoma. J Biomed Res. Aug 30–2015.Epub ahead of print. PubMed/NCBI
33	Gu X, Ding J, Zhang Z, Li Q, Zhuang X and Chen X: Polymeric nanocarriers for drugdelivery in osteosarcoma treatment. Curr Pharm Des. 21:5187–5197. 2015. View Article : Google Scholar
34	Sampson VB, Yoo S, Kumar A, Vetter NS and Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
35	Lim HJ and Yang JL: Regulatory roles and therapeutic potential of microRNA in sarcoma. Crit Rev Oncol Hematol. 97:118–130. 2016. View Article : Google Scholar
36	Morrow JJ and Khanna C: Osteosarcoma genetics and epigenetics: Emerging biology and candidate therapies. Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
37	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
38	Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J and Bonavida B: TRAF6 activation in multiple myeloma: A potential therapeutic target. Clin Lymphoma Myeloma Leuk. 12:155–163. 2012. View Article : Google Scholar : PubMed/NCBI
39	Kumar A, Bhatnagar S and Paul PK: TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 15:233–239. 2012. View Article : Google Scholar : PubMed/NCBI
40	Landström M: The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 42:585–589. 2010. View Article : Google Scholar : PubMed/NCBI
41	Yan J, Yin Y, Zhong W, Wang C and Wang Z: CD137 Regulates NFATc1 expression in mouse VSMCs through TRAF6/NF-kappaB p65 signaling pathway. Mediators Inflamm. 2015:6397802015. View Article : Google Scholar
42	Shi Z, Zhang Z, Zhang Z, Wang Y, Li C, Wang X, He F, Sun L, Jiao S, Shi W, et al: Structural Insights into mitochondrial antiviral signaling protein (MAVS)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling. J Biol Chem. 290:26811–26820. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tian X and Zhang X: A single nucleotide polymorphism (rs1056629) in 3′-UTR of MMP-9 is responsible for a decreased risk of metastatic osteosarcoma by compromising its interaction with microRNA-491-5p. Cell Physiol Biochem. 38:1415–1424. 2016. View Article : Google Scholar
44	Zhu Z, Tang J, Wang J, Duan G, Zhou L and Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
45	Wu S, Du X, Wu M, Du H, Shi X and Zhang T: MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-δ1. Gene. 584:83–89. 2016. View Article : Google Scholar : PubMed/NCBI
46	Bhattacharya S, Chalk AM, Ng AJ, Martin TJ, Zannettino AC, Purton LE, Lu J, Baker EK and Walkley CR: Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene. 35:5282–5294. 2016. View Article : Google Scholar : PubMed/NCBI
47	Pu Y, Zhao F, Cai W, Meng X, Li Y and Cai S: MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by downregulating Rab27B and SRR, respectively. Clin Exp Metastasis. 33:359–372. 2016. View Article : Google Scholar : PubMed/NCBI
48	Zhou L, Xu Z, Ren X, Chen K and Xin S: MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating Rho-associated protein kinase 1 (ROCK1). Cell Physiol Biochem. 38:1785–1795. 2016. View Article : Google Scholar
49	Deng D, Wang L, Chen Y, Li B, Xue L, Shao N, Wang Q, Xia X, Yang Y and Zhi F: miR-124-3p regulates cell proliferation, invasion, apoptosis and bioenergetics by targeting PIM1 in astrocytoma. Cancer Sci. 107:899–907. 2016. View Article : Google Scholar : PubMed/NCBI